19-288: Neoadjuvant TSR-042 (dostarlimab) for Patients with Rectal Adenocarcinoma
Condition: Rectal Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
Full Title
Protocol 19-288: A Phase II Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Eligibility
Stage II - III mismatch repair deficient or microsatellite instability high rectal adenocarcinoma eligible to receive neoadjuvant therapy as standard practice.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
